CD70-targeted PET/CT shows higher sensitivity than PSMA PET for clear cell RCC metastases
Prospective · Clin Cancer Res · 2026-11-07. Number 4 in the UrologyWatch Top 5 for November 8, 2026.
In a retrospective cohort of 128 patients and a prospective head-to-head study of 36 patients, CD70-targeted PET/CT ([68Ga]Ga-NOTA-RCCB6) showed higher sensitivity than PSMA PET ([68Ga]Ga-PSMA-11) for clear cell RCC (88.7% vs 76.1%, P<0.001), especially for lung and liver metastases. Among 26 evaluable patients, CD70 imaging improved lesion detection extent in 35% and changed treatment decisions in 15%.
Why it matters: New imaging data suggest CD70-targeted PET/CT may outperform PSMA PET for detecting clear cell RCC metastases, but findings come from a mixed retrospective/small prospective design and need larger validation.
Limitation: Small prospective cohort (36 patients) and retrospective comparator group; both imaging agents had limited sensitivity for non-clear-cell RCC.
Source: Clin Cancer Res · PubMed 42993177 · DOI 10.1158/1078-0432.ccr-26-2321
Loading today's edition…